Related Experiment Video
Updated: Aug 17, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Acute bronchospasm following administration of lidocaine
1Department of Oral Medicine and Periodontics, Faculty of Dentistry, University of Stellenbosch, Tygerberg, South Africa.
Abstract:
A 27-year-old woman with a history of Crohn's disease and an allergy to penicillin presented for routine restorative dental work. Xylotox E80A (3.6 mL of 2% lidocaine with 1:80,000 epinephrine) was given, and the dental work was completed uneventfully. Three months later she presented with acute pulpitis of a mandibular molar for which root canal therapy was indicated. At this time, 1.8 mL Xylotox E80A was given. Within 2 minutes, the patient experienced severe respiratory distress and the procedure was delayed for 5 days. In a fully equipped operating room, a subcutaneous test with Xylotox E80A was performed and acute bronchospasm resulted. This case report describes severe bronchospasm following the administration of lidocaine on two occasions.
Related Concept Videos
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Depolarizing Blockers: Mechanism of Action
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
Depolarizing Blockers: Pharmocokinetics
Local Anesthetics: Adverse Effects
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Cardiopulmonary Resuscitation IV: Pharmacological Management

